A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
Clinical trial NCT00077727 · COMPLETED
Trial details
- NCT number
- NCT00077727
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2003-03-01
- Enrollment
- 107
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.